Filing Details

Accession Number:
0001883850-22-000143
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-12-30 16:10:22
Reporting Period:
2022-12-28
Accepted Time:
2022-12-30 16:10:22
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
872589 Regeneron Pharmaceuticals Inc. REGN Pharmaceutical Preparations (2834) 133444607
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1197018 Anthony N Coles 777 Old Saw Mill River Road
Tarrytown NY 10591
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-12-28 2,145 $374.12 3,238 No 4 M Direct
Common Stock Acquisiton 2022-12-28 3,613 $482.68 6,851 No 4 M Direct
Common Stock Disposition 2022-12-28 181 $707.87 6,670 No 4 S Direct
Common Stock Disposition 2022-12-28 1 $709.92 6,669 No 4 S Direct
Common Stock Disposition 2022-12-28 679 $710.63 5,990 No 4 S Direct
Common Stock Disposition 2022-12-28 100 $711.95 5,890 No 4 S Direct
Common Stock Disposition 2022-12-28 1,198 $713.66 4,692 No 4 S Direct
Common Stock Disposition 2022-12-28 1,022 $714.61 3,670 No 4 S Direct
Common Stock Disposition 2022-12-28 2,266 $715.48 1,404 No 4 S Direct
Common Stock Disposition 2022-12-28 311 $716.08 1,093 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non-Qualified Stock Option (right to buy) Disposition 2022-12-28 2,145 $0.00 2,145 $374.12
Common Stock Non-Qualified Stock Option (right to buy) Disposition 2022-12-28 3,613 $0.00 3,613 $482.68
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2030-01-02 No 4 M Direct
0 2031-01-04 No 4 M Direct
Footnotes
  1. Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
  2. Represents volume-weighted average price of sales of 679 shares of Company stock on December 28, 2022 at prices ranging from $710.48 to $710.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 28, 2022 at each separate price.
  3. Represents volume-weighted average price of sales of 1,198 shares of Company stock on December 28, 2022 at prices ranging from $713.17 to $713.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 28, 2022 at each separate price.
  4. Represents volume-weighted average price of sales of 1,022 shares of Company stock on December 28, 2022 at prices ranging from $714.00 to $714.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 28, 2022 at each separate price.
  5. Represents volume-weighted average price of sales of 2,266 shares of Company stock on December 28, 2022 at prices ranging from $715.04 to $715.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 28, 2022 at each separate price.
  6. Represents volume-weighted average price of sales of 311 shares of Company stock on December 28, 2022 at prices ranging from $716.02 to $716.76. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 28, 2022 at each separate price.
  7. On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant.